Abstract
Background: Communicable disease control has long been a focus of global health policy. There have been substantial reductions in the burden and mortality of communicable diseases among children younger than 5 years, but we know less about this burden in older children and adolescents, and it is unclear whether current programmes and policies remain aligned with targets for intervention. This knowledge is especially important for policy and programmes in the context of the COVID-19 pandemic. We aimed to use the Global Burden of Disease (GBD) Study 2019 to systematically characterise the burden of communicable diseases across childhood and adolescence. Methods: In this systematic analysis of the GBD study from 1990 to 2019, all communicable diseases and their manifestations as modelled within GBD 2019 were included, categorised as 16 subgroups of common diseases or presentations. Data were reported for absolute count, prevalence, and incidence across measures of cause-specific mortality (deaths and years of life lost), disability (years lived with disability [YLDs]), and disease burden (disability-adjusted life-years [DALYs]) for children and adolescents aged 0–24 years. Data were reported across the Socio-demographic Index (SDI) and across time (1990–2019), and for 204 countries and territories. For HIV, we reported the mortality-to-incidence ratio (MIR) as a measure of health system performance. Findings: In 2019, there were 3·0 million deaths and 30·0 million years of healthy life lost to disability (as measured by YLDs), corresponding to 288·4 million DALYs from communicable diseases among children and adolescents globally (57·3% of total communicable disease burden across all ages). Over time, there has been a shift in communicable disease burden from young children to older children and adolescents (largely driven by the considerable reductions in children younger than 5 years and slower progress elsewhere), although children younger than 5 years still accounted for most of the communicable disease burden in 2019. Disease burden and mortality were predominantly in low-SDI settings, with high and high-middle SDI settings also having an appreciable burden of communicable disease morbidity (4·0 million YLDs in 2019 alone). Three cause groups (enteric infections, lower-respiratory-tract infections, and malaria) accounted for 59·8% of the global communicable disease burden in children and adolescents, with tuberculosis and HIV both emerging as important causes during adolescence. HIV was the only cause for which disease burden increased over time, particularly in children and adolescents older than 5 years, and especially in females. Excess MIRs for HIV were observed for males aged 15–19 years in low-SDI settings. Interpretation: Our analysis supports continued policy focus on enteric infections and lower-respiratory-tract infections, with orientation to children younger than 5 years in settings of low socioeconomic development. However, efforts should also be targeted to other conditions, particularly HIV, given its increased burden in older children and adolescents. Older children and adolescents also experience a large burden of communicable disease, further highlighting the need for efforts to extend beyond the first 5 years of life. Our analysis also identified substantial morbidity caused by communicable diseases affecting child and adolescent health across the world. Funding: The Australian National Health and Medical Research Council Centre for Research Excellence for Driving Investment in Global Adolescent Health and the Bill & Melinda Gates Foundation.
Original language | English |
---|---|
Pages (from-to) | 313-335 |
Number of pages | 23 |
Journal | The Lancet |
Volume | 402 |
Issue number | 10398 |
DOIs | |
Publication status | Published or Issued - 22 Jul 2023 |
ASJC Scopus subject areas
- General Medicine
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet, Vol. 402, No. 10398, 22.07.2023, p. 313-335.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990–2019
T2 - a systematic analysis of the Global Burden of Disease Study 2019
AU - GBD 2019 Child and Adolescent Communicable Disease Collaborators
AU - Azzopardi, Peter S.
AU - Kerr, Jessica A.
AU - Francis, Kate L.
AU - Sawyer, Susan M.
AU - Kennedy, Elissa Clare
AU - Steer, Andrew C.
AU - Graham, Stephen Michael
AU - Viner, Russell M.
AU - Ward, Joseph L.
AU - Hennegan, Julie
AU - Pham, Minh D.
AU - Habito, Christine Marie D.
AU - Kurji, Jaameeta
AU - Cini, Karly I.
AU - Beeson, James G.
AU - Brown, Alex
AU - Murray, Christopher J.L.
AU - Abbasi-Kangevari, Mohsen
AU - Abolhassani, Hassan
AU - Adekanmbi, Victor
AU - Agampodi, Suneth Buddhika
AU - Ahmed, Muktar Beshir
AU - Ajami, Marjan
AU - Akbarialiabad, Hossein
AU - Akbarzadeh-Khiavi, Mostafa
AU - AL-Ahdal, Tareq Mohammed Ali
AU - Ali, Musa Mohammed
AU - Samakkhah, Shohreh Alian
AU - Alimohamadi, Yousef
AU - Alipour, Vahid
AU - Al-Jumaily, Adel
AU - Amiri, Sohrab
AU - Amirzade-Iranaq, Mohammad Hosein
AU - Anoushiravani, Amir
AU - Anvari, Davood
AU - Arabloo, Jalal
AU - Arab-Zozani, Morteza
AU - Arkew, Mesay
AU - Armocida, Benedetta
AU - Asadi-Pooya, Ali A.
AU - Asemi, Zatollah
AU - Asgary, Saeed
AU - Athari, Seyyed Shamsadin
AU - Azami, Hiva
AU - Azangou-Khyavy, Mohammadreza
AU - Azizi, Hosein
AU - Bagheri, Nader
AU - Bagherieh, Sara
AU - Barone-Adesi, Francesco
AU - Barteit, Sandra
N1 - Funding Information: This research was funded by the Australian National Health and Medical Research Council and the Bill & Melinda Gates Foundation. Murdoch Children's Research Institute researchers were supported by the Australian Victorian Government's Operational Infrastructure Support Program. Core work was supported by the Australian National Health and Medical Research Council Centre for Research Excellence for Driving Investment in Global Adolescent Health (GNT 1171981). PSA is supported by a NHMRC Investigator grant GNT 2008574. S Barteit acknowledges support from the Heidelberg Institute of Global Health, Faculty of Medicine, University Hospital, Heidelberg University, Heidelberg, Germany. JGB acknowledges support from the National Health and Medical Research Council of Australia (investigator grant 1173046). LB acknowledges support from Fundação para a Ciência e Tecnologia in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of The Research Unit on Applied Molecular Biosciences from the Universities of Porto and NOVA of Lisbon and project LA/P/0140/2020 of i4HB. KIC acknowledges support from the Centre of Research Excellence in Driving Global Investment in Adolescent Health funded by NHMRC APP1171981. AF acknowledges support from the Department of Environmental Health Engineering of Isfahan University of Medical Sciences, Isfahan, Iran. SG acknowledges support from the Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, UK. RKG acknowledges support from Indore Institute of Pharmacy. JH acknowledges support from NHMRC investigator grant GNT2008600 and the Reckitt Global Hygiene Institute (RGHI); the views expressed are those of the authors and not necessarily those of RGHI. AGM acknowledges support from the NIHR Manchester Biomedical Research Centre and from an NIHR Clinical Lectureship in Respiratory Medicine. LM acknowledges support from the Italian Ministry of Health (Ricerca Corrente 34/2017), and payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. UOM acknowledges support from the German National Cohort Study Grant 01ER1801D. RRP acknowledges support from the University of Minnesota Doctoral Dissertation Fellowship. AR acknowledges support from the NPO Systemic Risk Institute number LX22NPO5101, funded by the European Union Next Generation EU (Ministry of Education, Youth, and Sports; NPO: EXCELES). AS acknowledges support from Health Data Research, UK. MRT-P acknowledges support from Saveetha Institute of Medical and Technical Sciences. JLW acknowledges support from an MRC Clinical Research Training Fellowship. AZ acknowledges support from The Pan-African Network on Emerging and Re-Emerging Infections supported by the EU and Developing Countries Clinical Trials Partnership, the EU Horizon 2020 Framework Programme, and from UK National Institute for Health and Care Research as a Senior Investigator Award and Mahathir Science Award winner, and The European and Developing Countries Clinical Trials Partnership (EU) Pascoal Mocumbi Prize Laureate. Researchers from Murdoch Children's Research Institute acknowledge support from the Victorian Government's Operational Infrastructure Support Program. We wish to acknowledge the extensive contributions to this paper by Prof George C Patton, who passed away in December, 2022 ( https://doi.org/10.1016/S0140-6736(22)02592-2 ). Prof George C Patton was an unwavering advocate for adolescent health and the importance of data to inform actions that are responsive to adolescents’ needs. Funding Information: This research was funded by the Australian National Health and Medical Research Council and the Bill & Melinda Gates Foundation. Murdoch Children's Research Institute researchers were supported by the Australian Victorian Government's Operational Infrastructure Support Program. Core work was supported by the Australian National Health and Medical Research Council Centre for Research Excellence for Driving Investment in Global Adolescent Health (GNT 1171981). PSA is supported by a NHMRC Investigator grant GNT 2008574. S Barteit acknowledges support from the Heidelberg Institute of Global Health, Faculty of Medicine, University Hospital, Heidelberg University, Heidelberg, Germany. JGB acknowledges support from the National Health and Medical Research Council of Australia (investigator grant 1173046). LB acknowledges support from Fundação para a Ciência e Tecnologia in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of The Research Unit on Applied Molecular Biosciences from the Universities of Porto and NOVA of Lisbon and project LA/P/0140/2020 of i4HB. KIC acknowledges support from the Centre of Research Excellence in Driving Global Investment in Adolescent Health funded by NHMRC APP1171981. AF acknowledges support from the Department of Environmental Health Engineering of Isfahan University of Medical Sciences, Isfahan, Iran. SG acknowledges support from the Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, UK. RKG acknowledges support from Indore Institute of Pharmacy. JH acknowledges support from NHMRC investigator grant GNT2008600 and the Reckitt Global Hygiene Institute (RGHI); the views expressed are those of the authors and not necessarily those of RGHI. AGM acknowledges support from the NIHR Manchester Biomedical Research Centre and from an NIHR Clinical Lectureship in Respiratory Medicine. LM acknowledges support from the Italian Ministry of Health (Ricerca Corrente 34/2017), and payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. UOM acknowledges support from the German National Cohort Study Grant 01ER1801D. RRP acknowledges support from the University of Minnesota Doctoral Dissertation Fellowship. AR acknowledges support from the NPO Systemic Risk Institute number LX22NPO5101, funded by the European Union Next Generation EU (Ministry of Education, Youth, and Sports; NPO: EXCELES). AS acknowledges support from Health Data Research, UK. MRT-P acknowledges support from Saveetha Institute of Medical and Technical Sciences. JLW acknowledges support from an MRC Clinical Research Training Fellowship. AZ acknowledges support from The Pan-African Network on Emerging and Re-Emerging Infections supported by the EU and Developing Countries Clinical Trials Partnership, the EU Horizon 2020 Framework Programme, and from UK National Institute for Health and Care Research as a Senior Investigator Award and Mahathir Science Award winner, and The European and Developing Countries Clinical Trials Partnership (EU) Pascoal Mocumbi Prize Laureate. Researchers from Murdoch Children's Research Institute acknowledge support from the Victorian Government's Operational Infrastructure Support Program. We wish to acknowledge the extensive contributions to this paper by Prof George C Patton, who passed away in December, 2022 (https://doi.org/10.1016/S0140-6736(22)02592-2). Prof George C Patton was an unwavering advocate for adolescent health and the importance of data to inform actions that are responsive to adolescents’ needs. Publisher Copyright: © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2023/7/22
Y1 - 2023/7/22
N2 - Background: Communicable disease control has long been a focus of global health policy. There have been substantial reductions in the burden and mortality of communicable diseases among children younger than 5 years, but we know less about this burden in older children and adolescents, and it is unclear whether current programmes and policies remain aligned with targets for intervention. This knowledge is especially important for policy and programmes in the context of the COVID-19 pandemic. We aimed to use the Global Burden of Disease (GBD) Study 2019 to systematically characterise the burden of communicable diseases across childhood and adolescence. Methods: In this systematic analysis of the GBD study from 1990 to 2019, all communicable diseases and their manifestations as modelled within GBD 2019 were included, categorised as 16 subgroups of common diseases or presentations. Data were reported for absolute count, prevalence, and incidence across measures of cause-specific mortality (deaths and years of life lost), disability (years lived with disability [YLDs]), and disease burden (disability-adjusted life-years [DALYs]) for children and adolescents aged 0–24 years. Data were reported across the Socio-demographic Index (SDI) and across time (1990–2019), and for 204 countries and territories. For HIV, we reported the mortality-to-incidence ratio (MIR) as a measure of health system performance. Findings: In 2019, there were 3·0 million deaths and 30·0 million years of healthy life lost to disability (as measured by YLDs), corresponding to 288·4 million DALYs from communicable diseases among children and adolescents globally (57·3% of total communicable disease burden across all ages). Over time, there has been a shift in communicable disease burden from young children to older children and adolescents (largely driven by the considerable reductions in children younger than 5 years and slower progress elsewhere), although children younger than 5 years still accounted for most of the communicable disease burden in 2019. Disease burden and mortality were predominantly in low-SDI settings, with high and high-middle SDI settings also having an appreciable burden of communicable disease morbidity (4·0 million YLDs in 2019 alone). Three cause groups (enteric infections, lower-respiratory-tract infections, and malaria) accounted for 59·8% of the global communicable disease burden in children and adolescents, with tuberculosis and HIV both emerging as important causes during adolescence. HIV was the only cause for which disease burden increased over time, particularly in children and adolescents older than 5 years, and especially in females. Excess MIRs for HIV were observed for males aged 15–19 years in low-SDI settings. Interpretation: Our analysis supports continued policy focus on enteric infections and lower-respiratory-tract infections, with orientation to children younger than 5 years in settings of low socioeconomic development. However, efforts should also be targeted to other conditions, particularly HIV, given its increased burden in older children and adolescents. Older children and adolescents also experience a large burden of communicable disease, further highlighting the need for efforts to extend beyond the first 5 years of life. Our analysis also identified substantial morbidity caused by communicable diseases affecting child and adolescent health across the world. Funding: The Australian National Health and Medical Research Council Centre for Research Excellence for Driving Investment in Global Adolescent Health and the Bill & Melinda Gates Foundation.
AB - Background: Communicable disease control has long been a focus of global health policy. There have been substantial reductions in the burden and mortality of communicable diseases among children younger than 5 years, but we know less about this burden in older children and adolescents, and it is unclear whether current programmes and policies remain aligned with targets for intervention. This knowledge is especially important for policy and programmes in the context of the COVID-19 pandemic. We aimed to use the Global Burden of Disease (GBD) Study 2019 to systematically characterise the burden of communicable diseases across childhood and adolescence. Methods: In this systematic analysis of the GBD study from 1990 to 2019, all communicable diseases and their manifestations as modelled within GBD 2019 were included, categorised as 16 subgroups of common diseases or presentations. Data were reported for absolute count, prevalence, and incidence across measures of cause-specific mortality (deaths and years of life lost), disability (years lived with disability [YLDs]), and disease burden (disability-adjusted life-years [DALYs]) for children and adolescents aged 0–24 years. Data were reported across the Socio-demographic Index (SDI) and across time (1990–2019), and for 204 countries and territories. For HIV, we reported the mortality-to-incidence ratio (MIR) as a measure of health system performance. Findings: In 2019, there were 3·0 million deaths and 30·0 million years of healthy life lost to disability (as measured by YLDs), corresponding to 288·4 million DALYs from communicable diseases among children and adolescents globally (57·3% of total communicable disease burden across all ages). Over time, there has been a shift in communicable disease burden from young children to older children and adolescents (largely driven by the considerable reductions in children younger than 5 years and slower progress elsewhere), although children younger than 5 years still accounted for most of the communicable disease burden in 2019. Disease burden and mortality were predominantly in low-SDI settings, with high and high-middle SDI settings also having an appreciable burden of communicable disease morbidity (4·0 million YLDs in 2019 alone). Three cause groups (enteric infections, lower-respiratory-tract infections, and malaria) accounted for 59·8% of the global communicable disease burden in children and adolescents, with tuberculosis and HIV both emerging as important causes during adolescence. HIV was the only cause for which disease burden increased over time, particularly in children and adolescents older than 5 years, and especially in females. Excess MIRs for HIV were observed for males aged 15–19 years in low-SDI settings. Interpretation: Our analysis supports continued policy focus on enteric infections and lower-respiratory-tract infections, with orientation to children younger than 5 years in settings of low socioeconomic development. However, efforts should also be targeted to other conditions, particularly HIV, given its increased burden in older children and adolescents. Older children and adolescents also experience a large burden of communicable disease, further highlighting the need for efforts to extend beyond the first 5 years of life. Our analysis also identified substantial morbidity caused by communicable diseases affecting child and adolescent health across the world. Funding: The Australian National Health and Medical Research Council Centre for Research Excellence for Driving Investment in Global Adolescent Health and the Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85165033050&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(23)00860-7
DO - 10.1016/S0140-6736(23)00860-7
M3 - Article
C2 - 37393924
AN - SCOPUS:85165033050
SN - 0140-6736
VL - 402
SP - 313
EP - 335
JO - The Lancet
JF - The Lancet
IS - 10398
ER -